ACD-856

First-in-class small-molecule positive allosteric modulator of all three Trk receptors (TrkA/TrkB/TrkC) — the receptors that BDNF, NGF, and NT-3 sit on. Doesn't activate the receptor by itself; it makes endogenous neurotrophin signaling more effective when it happens. Phase 1 SAD + MAD + Phase 1b complete (last patient April 2026), excellent safety profile, oral, ~19 hr half-life, BBB penetrates at 37–120% CSF/plasma. No human efficacy data yet. Phase 2a in Alzheimer's funded by €2.5M EU EIC grant (paid Dec 2025), study prep underway Q1 2026. For Dylan: WATCH-LIST. Mechanism is one of the cleanest in the entire neurotrophic pipeline, but it is too early for self-experimentation, the only research-chem vendor (Everychem) is on his AVOID list, and there is no human cognitive-enhancement readout to anchor a decision. Revisit when Phase 2a reads out.

ACD-856 is a triazinetrione-class small molecule developed by AlzeCure Pharma (Sweden) under their NeuroRestore platform (ACD856 lead, ACD857 + ACD679 + ACD680 follow-ons). Structurally derived from optimization of ponazuril (ACD855) and toltrazuril (veterinary anticoccidials whose CNS effects were repurposed). The exact published structure remains undisclosed as of 2026; protected by US patent 11,352,332 and equivalents in CN/IN/IL/HK/MX/ZA, all valid until 2039.

Receptor binding (per Nordvall et al., AlzeCure team):

• TrkA EC50 = 382 nM
• TrkB EC50 = 295 nM
• TrkC EC50 ≈ 330 nM
• Lower-efficacy modulation also reported at IGF1R and FGFR1 (off-target but related kinase family)

The PAM (positive allosteric modulator) trick — plain English:

Tropomyosin receptor kinases (Trks) are the receptors that BDNF, NGF, and NT-3 bind to on neurons. When a neurotrophin binds, the receptor's intracellular kinase domain phosphorylates itself and triggers three big downstream cascades:

1. MAPK / ERK1/2 → neurite outgrowth, synaptic plasticity, long-term potentiation (the molecular substrate of memory)
2. PI3K / Akt → cell survival, anti-apoptosis (Bcl-2 up, Bax down, caspase-3 suppressed)
3. PLCγ → intracellular calcium signaling, transcriptional changes

The problem with directly activating Trks (the dihexa / 7,8-DHF / "BDNF mimetic" approach) is that constant high-amplitude Trk signaling has theoretical risks: TrkA agonism is involved in pain signaling (NGF antibodies like tanezumab were developed for pain), and chronic TrkB agonism may downregulate the receptor, may have pro-tumorigenic effects in certain contexts, or may trigger seizures (tonic-clonic seizures have been reported with some BDNF-mimetic compounds in animals).

ACD-856 sidesteps this by binding the intracellular kinase domain rather than the extracellular ligand-binding site. It increases the Vmax of TrkA's kinase activity — i.e., when BDNF or NGF does bind, the receptor does its job harder and faster. It does nothing in the absence of endogenous neurotrophin. This means:

• Signal is amplified only where BDNF/NGF is being released → preserves the spatial and temporal pattern of endogenous neurotrophin signaling
• Less risk of receptor downregulation than a tonic agonist
• Mechanistically distinct from cerebrolysin (peptide cocktail that mimics BDNF/NGF), dihexa (HGF activator → indirect Trk pathway), or 7,8-DHF (direct TrkB agonist)

Downstream effects observed in cells:

• ↑ phospho-TrkB in SH-SY5Y neuroblastoma cells
• ↑ phospho-ERK1/2 in primary cortical neurons
• ↑ NGF-induced neurite outgrowth in PC12 cells
• ↑ pre-synaptic protein SNAP-25 levels
• ↑ BDNF protein expression ~30% in neuronal cultures (auto-amplifying loop — Trk-PAM activity drives transcription of more BDNF)
• Neuroprotection vs amyloid-beta toxicity
• Neuroprotection vs energy-deprivation (glucose/oxygen withdrawal models)
• Improved mitochondrial function (newer 2024–2026 data)

In live animals (rats / mice):

• Facilitates LTP (long-term potentiation) in hippocampal slices
• Increases brain acetylcholine in awake rats (microdialysis)
• Reverses scopolamine-induced memory impairment (cholinergic blockade model)
• Reverses dizocilpine (MK-801)-induced memory impairment (NMDA blockade model)
• Reverses age-related memory deficits in old mice
• Sustained antidepressant-like activity in forced-swim and tail-suspension tests
• Anti-inflammatory effects (cytokine downregulation in neuroinflammation models)

The animal data covers two distinct memory-impairment mechanisms (cholinergic + glutamatergic) and an aging model — broader pharmacological coverage than typical for a single compound, which is what you'd expect from a mechanism that amplifies whatever neurotrophic signaling is happening rather than hitting a single neurotransmitter system.